On April 15, President Trump issued an executive order aimed at lowering prescription drug prices that requires the FDA commissioner to issue a report within 180 days “providing administrative and legislative recommendations to accelerate approval of generics, biosimilars, combination products, and second-in-class brand name medications.”
In a fact sheet the White House summarized efforts to increase the availability of generics and biosimilars through measures including:
- improved